One in five people treated for a serious heart attack with modern stents still run into major trouble in the exact spot that was fixed—up to a decade later. And this is the part most people miss: even when the initial procedure goes smoothly, long‑term risk in that “treated segment” of the artery remains very real.
TOPLINE
In a large Danish study following patients with ST‑segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI), about 20% experienced target lesion failure (TLF) within 10 years, meaning the specific artery segment that was stented later caused serious problems again. Older age and the presence of other medical conditions significantly increased this long‑term risk, underscoring that the story does not end once the artery is opened in the cath lab.
METHODOLOGY
Researchers drew on data from the DANAMI‑3 trial, focusing on 2217 patients who had a STEMI and were treated with primary PCI at four heart centers in Denmark between 2011 and 2014. The group was predominantly male (roughly three‑quarters of participants) and had a median age in the early to mid‑60s, which is typical for many heart‑attack cohorts but still represents a relatively broad age range.
Target lesion failure was defined as a combined outcome that included cardiovascular death, a new myocardial infarction in the same target lesion (TL MI), or the need for another revascularization procedure in that same segment of the coronary artery. Outcomes were assessed over a median follow‑up of 10.7 years, giving the investigators a long window to see how that originally treated spot behaved over time.
As a secondary layer of analysis, the team looked at a broader, patient‑oriented composite of major adverse cardiac events to understand how TLF fit into the overall burden of serious cardiovascular complications. To better identify who might be especially vulnerable, they defined a high‑risk subgroup: patients older than 70 years who also had at least one additional risk marker—hypertension, a previous acute myocardial infarction, or a Killip class of II–IV at presentation, indicating more advanced heart‑failure status. Just over half of the cohort, 53.9%, fell into this high‑risk category, highlighting how common multiple risk factors are among STEMI patients.
TAKEAWAY
By the 10‑year mark after PCI, 20% of patients had experienced target lesion failure, with 5.6% of events occurring in the first year and then continuing at a fairly steady rate of about 1.6% per year thereafter. This pattern suggests that while the earliest period after stent placement is hazardous, the risk does not vanish over time—it simply shifts into a slow, ongoing drip of events.
Several clinical factors independently predicted a higher likelihood of TLF: older age, a history of hypertension, prior acute myocardial infarction, and being in Killip class II–IV at the time of the index event; each of these was strongly associated with increased risk on statistical testing (P < .01). In contrast, use of second‑generation drug‑eluting stents was associated with a significantly lower risk of TLF (P = .005), reinforcing the view that newer‑generation stent technology does appear to translate into better long‑term outcomes at the lesion level.
When the investigators compared risk groups, patients in the predefined high‑risk category had more than double the chance of experiencing TLF compared with those in the low‑risk group (P < .001). Perhaps most striking from a clinical‑impact standpoint, target lesion failure was responsible for 46% of all patient‑oriented major adverse cardiac events, meaning nearly half of the most serious long‑term problems could be traced back to the originally treated lesion. This raises a provocative question: should follow‑up care focus much more aggressively on that specific stented segment rather than treating it as “fixed” once the patient leaves the hospital?
IN PRACTICE
The investigators emphasized that their findings highlight a growing need to pay closer attention to long‑term prevention of target lesion failure rather than viewing PCI as a one‑time cure. In practical terms, this might translate into more individualized follow‑up, stricter attention to risk‑factor control, and more careful selection of stent type and procedural strategy, especially for older or high‑risk patients.
For clinicians, the message is uncomfortable but important: even with contemporary PCI and advanced stent designs, a substantial proportion of serious events a decade later are still tied to the original lesion. But here’s where it gets controversial: should cardiology guidelines push for more routine long‑term imaging or functional testing of stented segments in high‑risk patients, or would that lead to over‑treatment and unnecessary procedures?
SOURCE
The study was led by Burcu Tas Özbek from Rigshospitalet Hjertecentret in Copenhagen, Denmark, and the full report was published online in the journal Open Heart on November 13, 2025 (Open Heart, volume 12, issue 2, article e003588). The publication offers more detailed statistical modeling and subgroup analyses for readers who want to explore the nuances of the data and methodology.
LIMITATIONS
Like any long‑term observational analysis, this work comes with important caveats. STEMI care evolved substantially over the decade in question, including changes in pharmacotherapy, devices, and procedural techniques, which may limit how directly the findings apply to patients treated under today’s protocols.
In addition, after the initial 5‑year follow‑up period, clinical events were collected retrospectively from medical records and national registries rather than through ongoing, prospectively adjudicated surveillance. Events occurring beyond 5 years were not reviewed by an independent clinical events committee, which introduces the possibility of misclassification or under‑reporting and should be kept in mind when interpreting late outcomes.
DISCLOSURES
The investigators reported that the study did not receive specific external funding earmarked for this analysis. They also stated that they had no conflicts of interest to declare, which may reassure readers concerned about financial or industry‑related bias influencing the design, conduct, or reporting of the trial.
As a final note of transparency, the article describing these findings was developed using multiple editorial tools, including artificial intelligence, as part of the writing and production workflow. Human editors reviewed and refined the content before publication to ensure accuracy, clarity, and adherence to journal standards.
A question for you: Do these data make you think current follow‑up after STEMI PCI is too relaxed, especially for older or high‑risk patients—or do you feel more aggressive surveillance and intervention could actually do more harm than good? Share where you stand and why—you may not agree with the implications of this study, and that disagreement is exactly what pushes the field forward.
